WASHINGTON — Seeking new ways to lower drug prices, White House advisers have raised the prospect of fast-tracking the review process for some brand-name medications submitted for approval to the Food and Drug Administration.

The FDA already prioritizes the review of drugs that are the first, second, and third generics of any given brand. The new idea, outlined in a report from the Council of Economic Advisers released Friday, might expand such a policy to brand-name drugs that treat similar diseases but can’t be interchanged like generics can be.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy